Company:  EMMAUS LIFE SCIENCES, INC ... (EMMA)
Form Type:  4
Filing Date:  6/2/2020 
CIK:  0000822370 
Address:  21250 HAWTHORNE BOULEVARD, SUITE 800 
City, State, Zip:  TORRANCE, California 90503 
Telephone:  310-214-0065 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$1.43  
Change: 
-0.16 (-10.06%)  
Trade Time: 
Jun 11  
Market Cap: 
$70.52M
Trade EMMA now with 

© 2021  
Description of Business
In this Annual Report, the terms, "we," "us," "our" or the "Company" refer to Emmaus Life Sciences, Inc., and its subsidiaries. Overview We are a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, primarily for rare and orphan diseases. On July 7, 2017, our lead product, Endari® (prescription grade L-glutamine oral powder), was approved by the U.S. Food and Drug Administration, or FDA, to reduce the acute complications of sickle cell disease ("SCD") in adult and pediatric patients five years of age and older. Endari® has received Orphan Drug designation from the FDA and Orphan Medicinal designation from the European Commission, which designations afford marketing exclusivity for Endari® for a seven-year period in the U.S. and ten-year period in the European Union, respectively, following marketing approval. Endari® is marketed and sold in the U.S.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES